GlaxoSmithKline ((GSK)), GlaxoSmithKline plc (UK) ((GB:GSK)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
GlaxoSmithKline (GSK) is conducting a Phase IIb clinical study titled A Phase IIb, Randomized, Observer-Blind Study to Describe the Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents. The study aims to evaluate the safety, tolerability, and immunogenicity of the MenABCWY vaccine, which targets five meningococcal serogroups to prevent invasive meningococcal disease (IMD) in adolescents.
The intervention involves administering the MenABCWY vaccine, a combination product, to participants in two experimental groups. The ABCWY-24 Group receives the vaccine on a 0-, 24-month schedule, while the ABCWY-48 Group follows a 0-, 48-month schedule. A placebo is also administered as part of the study design.
This interventional study is randomized and follows a parallel assignment model. It is observer-blind, meaning participants, care providers, investigators, and outcomes assessors are unaware of the specific vaccine administered. The primary purpose of the study is prevention.
The study began on November 18, 2021, with an estimated completion date yet to be confirmed. The latest update was submitted on August 6, 2025, indicating ongoing progress in the study.
This update from GSK could influence investor sentiment positively, as successful development of the MenABCWY vaccine could enhance GSK’s market position in the vaccine industry. The study’s progress may also impact the stock performance of GSK, especially if the results show promising safety and efficacy outcomes compared to competitors.
The study is currently active but not recruiting, with further details available on the ClinicalTrials portal.